title: Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.
abstract: Considering that the prostate cancer radioresistance occurs in a significant percentage--as 20-40% of prostate cancer (PCa) patients undergone external beam radiation therapy developing, within ten years, recurrent and more aggressive tumor--the resort to customized radiosensitizer measures, focusly targeting PCa radioresistance-linked individual molecular aberrations, can increase the successful outcomes of PCa radiotherapy.
authors.forename: C
authors.initials: C
authors.lastname: Alberti
mesh_terms: D017209:Apoptosis / Q000187:drug effects* / Q000528:radiation effects; D015894:Genome, Human / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000532:radiotherapy*; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011838:Radiation-Sensitizing Agents